[Cerebrospinal fluid distributions of systemically administered fluorinated pyrimidines].
Transfer of systemically administered fluorinated pyrimidines (Tegafur, TAC-278, HCFU and FD-1) to cerebrospinal fluid was studied in 7 patients primary brain tumors. Seven patients had had irradiation and also had V-P shunt operation for hydrocephalus 5-FU concentration in CSF was extremely high in FD-1 and TAC-278 administration, but not in Tegafur and HCFU administration. In addition, Tegafur and HCFU did not reveal any cumulative effects of 5-FU in CSF by continuous prolonged systemic administration. The facts suggest strongly the usefullness of the agents in the treatment of intracranial neoplasms, which have high CSF concentrations. However, intermediate metabolites of 5-FU in CSF are different from those in systemic pathway, and FD-1 and TAC-278 produce CNS toxicities. Therefore, further extensive studies are necessary to utilize these agents for the treatment of intracranial neoplasms.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000134:cerebrospinal fluid*; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid*; D004806:Ependymoma / Q000134:cerebrospinal fluid; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D005909:Glioblastoma / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid
D000970:Antineoplastic Agents; D005641:Tegafur; C016882:FD 1; C036428:TAC 278; C017367:carmofur; D005472:Fluorouracil